Overview

A Study to Assess the Effect of Abiraterone Acetate in Male Participants With Mild or Moderate Hepatic Impairment Compared to Matched Control Participants With Normal Hepatic Function

Status:
Completed

Trial end date:
2010-04-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety and pharmacokinetics (study of what the body does to a drug) of 1000 mg oral dose of abiraterone acetate and its major metabolite(s) with mild or moderate hepatic impairment and matched control Participants with normal hepatic function.

Phase:

Phase 1

Details

Lead Sponsor:

Cougar Biotechnology, Inc.

Treatments:

Abiraterone Acetate